Analysts think CGON stock price could increase by 176%
May 15, 2025, 11:25 AM
6.92%
What does CGON do
CG Oncology, based in Irvine, California, focuses on developing bladder-sparing therapies for bladder cancer and went public on January 25, 2024. Its key candidates include cretostimogene and BOND-003, both targeting non-muscle invasive bladder cancer.
11 analysts think CGON stock price will increase by 176.13%. The current median analyst target is $66.81 compared to a current stock price of $24.20. The lowest analysts target is $23.23 and the highest analyst target is $86.10.
📡️ Health Care
Price Target
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
